Merck & Co makes huge gains on molnupiravir breakthrough in COVID-19

1 October 2021
merck_large

Results on Merck & Co (NYSE: MRK) and Ridgeback Biotherapeutics’ molnupiravir massively impacted not just the share price of the US pharma giant and its competitors on Friday, but could also have a significant effect on the COVID-19 pandemic itself.

Merck’s shares closed nearly 10% higher on Friday after the announcement of interim Phase III results, which showed that the investigational antiviral pill significantly reduced the risk of hospitalization or death in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19.

"Antiviral treatments that can be taken at home to keep people with COVID-19 out of the hospital are critically needed"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology